FAP Protein, Human, Recombinant (His Tag)

1/1
Price:
Size:
Number:

FAP Protein, Human, Recombinant (His Tag): Product Information

Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Measured by its ability to convert the substrate benzyloxycarbonyl-Gly-Pro-7-amido-4-methylcoumarin (Z-GP-AMC) to Z-Gly-Pro and 7-amino-4-methylcoumarin (AMC).
The specific activity is >1200 pmol/min/μg
Protein Construction
A DNA sequence encoding the human FAP isoform 1 (Q12884-1) extracellular domain (Leu 26-Asp 760) was fused with the polyhistidie-tag at the N-terminus.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
His
Molecule Mass
The recombinant human FAP consists of 751 amino acids and predicts a molecular mass of 87.2 kDa. As a result of glycosylation, rh FAP migrates as approximately 90 kDa band in SDS-PAGE under reducing conditions.
Formulation
Supplied as sterile 25mM Tris, 250mM NaCl, pH 8.2
Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
Kinases are highly recommended to be shipped at frozen temperature with blue ice or dry ice.
Shipment made at ambient temperature may seriously affect the activity of the ordered products.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

FAP Protein, Human, Recombinant (His Tag): Images

FAP Protein, Human, Recombinant (His Tag): Synonyms

DPPIV Protein, Human; DPPIVA Protein, Human; FAPA Protein, Human; Fapalpha Protein, Human; Fibroblast Activation Protein alpha Protein, Human; SIMP Protein, Human

FAP Background Information

Seprase, also known as 17 kDa melanoma membrane-bound gelatinase , Fibroblast activation protein alpha, Integral membrane serine protease and FAP, is a single-pass type II membrane protein which belongs to thepeptidase S9B family. Seprase / FAP is found in cell surface lamellipodia, invadopodia and on shed vesicles. Seprase / FAP appears to act as a proteolytically active 17-kDa dimer, consisting of two 97-kDa subunits. It is a member of the group type II integral serine proteases, which includes dipeptidyl peptidase IV ( DPPIV / CD26 ) and related type II transmembrane prolyl serine peptidases, which exert their mechanisms of action on the cell surface. Seprase / FAP colocalized with DPP4 in invadopodia and lamellipodia of migratory activated endothelial cells in collagenous matrix. Seprase / FAP colocalized with DPP4 on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma. DPP4 and seprase exhibit multiple functions due to their abilities to form complexes with each other and to interact with other membrane-associated molecules. In association with DPP4, Seprase / FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. Seprase / FAP has a dual function in tumour progression. The proteolytic activity of Seprase has been shown to promote cell invasiveness towards the ECM and also to support tumour growth and proliferation. Seprase / FAP may have a role in tissue remodeling during development and wound healing, and may contribute to invasiveness in malignant cancers.
Full Name
fibroblast activation protein, alpha
References
  • Mori,Y. et al., 2004, Oncology. 67 (5-6):411-9.
  • Aertgeerts K., et al., 2005, J. Biol. Chem. 280:19441-19444.
  • Liu T., et al., 2005, J. Proteome Res. 4:2070-2080.
  • Ghersi G., et al., 2006, Cancer Res. 66:4652-4661.
  • O'Brien,P. et al., 2008, Biochim Biophys Acta. 1784 (9):1130-45.
  • Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy
    Author
    Yu, Q;Qiu, Y;Li, J;Tang, X;Wang, X;Cun, X;Xu, S;Liu, Y;Li, M;Zhang, Z;He, Q;
    Year
    2020
    Journal
    J Control Release
    Application
    cell-based
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.